Scientific Sessions:
“World Congress on Clinical Research and Biomarkers-2019”




Clinical Trials:

One of the big challenges in medical research is to perform clinical trials in developing countries that will go ahead to therapies that Benefit the citizens of these countries. Harold Shapiro and Eric Meslin are National Bioethics Advisory Commission’s (NBAC)
Chair and Executive Director they summarize their committee’s positions in moral issues in Design and conduct of clinical trials in developing countries. The past year has seen much discussion on participation by physicians from developed countries in research conducted in less-developed countries. Trails that make use of unprepared populations to test drug for use not involving anything in developed countries break our most essential understanding of ethical behavior. The clinical research process begins with clinical testing on animals and then submission on trial new drug application to the Food and Drug Administration (FDA).

Innovations in Clinical Trials:



Researchers and Policymakers are continuously Focusing  on factors that facilitates  or prevent   transmission of confirmation-based  treatment techniques into routine clinical practice .clinical review pattern involves the amount of study volunteers, their division in view of differing variables and their treatment all through the clinical trial handle .as of late, the utilization and  adaptive plan techniques in clinical research has turned out to be increasingly well known because of its flexibility and effectiveness. The examiner show that, controlling for variety of organizational characteristics, direct exposure to buprenorphine clinical trials in the clinical Trail  notification(CTN) Significantly increased the odds of subsequent adoption. By contrast, the adoption of motivational incentives was entirely explained by the organizational characteristics.




                                                          

Clinical Trials on Different Diseases:

 
The clinical research council has for some years encouraged mutual clinical trials in Blood cancer and other cancers, reporting the result in the literature. In the context of Modern, evidence-based prevention and treatment of infectious diseases clinical trial provide information about the accuracy of molecular or microbiological diagnostics the prognosis of infectious syndromes and the potential risks and benefits of anti-infective regimens. However, there is a paucity of clinical Trails informing specific questions faced by infectious specialists.


To attend the Clinical Research and Biomarkers-2019 conference Contact:

Name: Sam Watson
Occupation: WCCRB-2019 Program Coordinator 
Conference Website: https://scientificfederation.com/clinical-biomarkers-2019/#
Email: biomarkersresearch@gmail.com
Phone: +91-779-979-0002
Continue Reading

P- glycoprotein




WCCRB-2018
Scientific Federation invites all the participants from all over the world to attend 2nd World Congress on Clinical Research & Biomarkers during September 17-18, 2018 Toronto, Canada. 
Human natural killer cells are a population of large granular lymphocytes which can lyses tumor target cells in vitro without prior sensitization and with no major histocompatibility complex restriction. Lymph proliferative diseases of large granular lymphocytes can arise from T lymphocytes or natural killer cells. Large granular lymphocyte leukemia’s derived from T lymphocytes generally follow an indolent course with a median survival time exceeding many years. However, large granular leukemia’s involving natural killer cells are typically very aggressive and patients have a median survival time of two months due to being refractory to multi-agent chemotherapy. The World Health Organization classifies natural killer cell malignancies into three categories, including aggressive natural killer cell leukemia, extra nodal natural killer lymphoma and blastic natural killer cell lymphoma.
Though studies are sparse, natural killer cell malignancies seem to be relatively rare in Caucasians, but the incidence rises significantly in Asian and South American populations. One potentially promising approach is through the use of statins drugs. Statins have been used to lower LDL cholesterol levels in those with hypercholesterolemia and have been shown to have a limited number of side effects. Commonly prescribed statins include lovastatin, simvastatin, atorvastatin; fluvastatin, pravastatin, and rosuvastatin calcium. It shown that statins can have anti-inflammatory and immune modulator effects. In addition, statins may have potent anti-tumor properties.
In terms of the effect of statins on natural killer cell leukemias, a clinical case report noted that treatment with a farnesyl transferase inhibitor, which interrupts the mevalonate pathway farther downstream than the statins, resulted in clinical improvement and, importantly, a reduction of pulmonary artery hypertension. The pulmonary hypertension has been connected to damage to the pulmonary endothelial cells as a result of leukemic natural killer cell cytotoxicity. The novel effect of statins on leukemia cells is a new and potentially exciting field of research.

In the current research utilized the cell line YT-INDY to investigate the effect of statins on natural killer leukemic cells. The parental YT cell line is an interleukin-2-independent human leukemia natural killer cell line that has been used in numerous studies to investigate normal natural killer cell function. YT cells were isolated originally from a boy with acute lymphoblastic lymphoma. Investigations were performed because aggressive natural killer cell leukemias are devastating diseases which are nearly always fatal within weeks or, at best, a few months of diagnosis. Multi-agent chemotherapy has failed in the majority of patients with this disease. Therefore, new approaches to treatment must be developed that can provide a cure or significant life extension.
Continue Reading

Lymphoma



WCCRB-2018
Scientific Federation invites all the participants from all over the world to attend 2nd World Congress on Clinical Research & Biomarkers during September 17-18, 2018 Toronto, Canada. 
There are many number of Lymphoma in pathology few of them are
Malignant lymphoma mainly includes Non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL). Its incidence is increasing and now ranges among the tenth most frequent cancers worldwide.

Mantle cell lymphoma (MCL) is an aggressive B-NHL that arises from naïve B cells in the mantle zone of the lymph nodes. It is characterized by translocation and subsequent over expression of CCND1.

Methylation study in Mantle cell lymphoma cell lines found in different expressed genes mapped to autosomal chromosomes. Pathway analysis revealed that top cellular functions represented cell death, cell cycle, cellular growth and proliferation. Mass ARRAY assay of 25 candidate genes in seven MCL cell lines and normal B cells showed genes hyper ethylated in more than one MCL cell line, encompassing cell differentiation, cell adhesion, cell cycle and apoptosis p53 pathway and PI3K pathway, transcription factors and many unknown functions are there in MCL

Hodgkin’s lymphoma (HL) Screening of methylated genes was performed in HL KM-H2 cell line by microarray analysis before and after treatment with 5-aza-2’-deoxycitidine. Thirty tumor suppressive genes were identified, including genes in cellular adhesion, growth arrest p53 pathway and two transcription factors. Among them was further confirmed methylated and down-regulated in primary HL cells. Restoration of CADM1 expression in HL cells decreased cell survival and increased their sensitivity to apoptosis, demonstrating that IGSF4silencing by CpG methylation inhibited apoptosis in Reed-Sternberg cells, which was an important process in HL pathogenesis.
Continue Reading

Alpha-Fetoprotein







WCCRB-2018

Being an Organizing Committee Member at 2nd World Congress on Clinical Research & Biomarkers Conference held by Scientific Federation is invited as Speaker for this conference. Vladimir N. Pak has completed his PhD from Moscow Institute of Bioorganic Chemistry, Russia and has over 30 years of post-doctoral experience in virology, immunology, biotechnology, pharmacology and oncology. He has published 7 patents related to API research and medicines manufacturing. He is the inventor of the anti-cancer medicines based on alpha-fetoprotein (AFP)-toxin non-covalent complexes that act as a targeted chemotherapy and MDSCs-immunotherapy. As a freelance researcher I need to know what kind of discount you can provide to me.



Alpha-fetoprotein (AFP) is a pregnancy biomarker. The protein shuttles essential nutrients to AFP receptor (AFPR)-positive embryonic cells. For majority of cancers AFPR is a biomarker and it is also expressed by host myeloid-derived suppressor cells (MDSCs).AFP delivers selected nutrients to MDSCs that suppress innate and adaptive immunity during cancer, inflammation, hemopoiesis and regeneration.AFP loaded with a medicine can be helpful in treating autoimmune diseases and inflammation, in transplantation, etc. On the other hand, AFP loaded with a toxin can destroy cancer cells and MDSCs. MDSCs depletion unleashes innate and adaptive immunity to remove cancer cells. In addition to traditional use as a pregnancy and tumor biomarker AFP obtains the new immunotherapy drug use.
Continue Reading

Lung Cancer


WCCRB-2018

Scientific Federation invites all the participants from all over the world to attend 2nd World Congress on Clinical Research & Biomarkers during September 17-18, 2018 Toronto, Canada.
Now a day’s cancer is very dangerous disease and an especially lung cancer plays major role. Blood based biomarkers have potential in cancer screening and their role could extend further from general population risk assessment to treatment response evaluation and recurrence monitoring. The rich content of diverse cellular and molecular elements in blood, which provide information about the health status of an individual, makes it an ideal compartment to develop noninvasive diagnostics for cancer. Other common cancers, notably breast and lung cancer, lack established biomarkers with demonstrated clinical utility in a screening setting. There is a need for biomarkers with the required sensitivity and specificity for the detection of frequently occurring cancer types. Protein markers currently in clinical use, which include Cancer antigen 125 for ovarian cancer, Carbohydrate antigen 199 for pancreatic cancer, Carcino embryonic antigen for colon cancer and Prostate specific antigen for prostate cancer, have limitations with respect to their use for screening owing to low sensitivity and specificity in early stages and inability to distinguish aggressive from indolent tumors.
This is significantly more sensitive than the most sensitive detection methods from electrophoretic gels with silver staining or fluorescence staining, or the general mass spectrometry methods. Secondly, it is known that many proteins have post-translational modifications (PTMs) and splice variants; these different forms of the same gene product may have different functions/enzyme activities and play very different roles in biology. However the important information on the impact of PTM and protein splicing is lost in the antibody, LC-MS or gel-based analysis because these platforms cannot directly measure the functional features of the proteome. The introduction of exogenous protein(s) from the PEP samples could potentially supersede any rate-limiting protein function and enhance the hexokinase activity. As such, this assay may also detect the effect of proteins from other pathways that cross-interact with the glycol tic pathway.

PS: http://scientificfederation.com/clinical-research-2018/
Continue Reading

Dietary Biomarkers


WCCRB-2018 Dietary Biomarkers

Traditional methods for assessing dietary exposure can be unreliable, with under reporting one of the main problems. In an attempt to overcome such problems there is increasing interest in identifying biomarkers of dietary intake to provide a more accurate measurement. Metabolomics is an analytical technique that aims to identify and quantify small metabolites. Recently, there has been an increased interest in the application of metabolomics coupled with statistical analysis for the identification of dietary biomarkers, with a number of putative biomarkers identified. Dietary biomarkers rule out this problem, and highlight that dietary suggestions to avoid red meat and saturated fat and increase uptake of plant-based oils and whole grains seems to hold it true, at least in this group of women.

Diet is an important factor assessing point in developing type 2 diabetes whole grains, vegetable oils and good vitamin E status found to be primary aspects against type 2 diabetes, whereas saturated fat and meat increased the chances for developing the disease. It was very fortunate that researchers were able to reach these conclusions without having any additional data on diet through the subjects.

 Down the line blood samples were collected, where a unique metabolic fingerprint, including many different diet biomarkers, could be linked to each woman at the specific time the sample was taken. Using this method it was possible for the first time to objectively determine the impact of key dietary components on future type 2 diabetes risks, as well as to compare the dietary patterns between women having and without having type 2 diabetes. The new method has allowed scientists to measure several markers of diet and nutrient status at the same time in a large number of people, which they believed is the pioneering one in this area.

The role of diet is generally discussed as a preventative strategy for developing type 2 diabetes, this new research provides strong evidence for dietary guidelines, and underlines the significance of changing diet to improve health. Collecting information about diet can be complicated and time consuming, and is always biased by what people remember and think they should report. New methods such as this shall contribute to recover how we measure diet and understand in more detail how dietary patterns relate to disease.

To have more information about the dietary biomarkers please join our conference. Clinical Research and Biomarkers (WCCRB-2018) which is during September 17-18, 2018 at Toronto, Canada
Link: http://scientificfederation.com/clinical-research-2018/
Continue Reading

Biomarkers in the Health and Depression Disorder


WCCRB-2018




Biomarkers are used in all health fields to aid in the diagnosis of illnesses. By definition, biomarkers are a measurable substance that is an indicator of a distinct disease, infection, or environmental exposure.  Biomarkers include ions, genetic markers, proteins, and structural abnormalities. Mental health scientists are currently working on many different biomarkers in order to help define, identify, and effectively treat mental illnesses. A biomarker in mental health is blood testing and urine sampling, which is now being used to detect disorders such as Alzheimer’s disease and Major Depressive Disorder.

The next most common form of depression is Low-Folate depression folate is one of the B-vitamins. Folaters’ primary job is to convert B12 Vitamin into a different form so it can be used in DNA synthesis. Foliate is also involved in cell growth. There is a specific form of folate that has access to the brain. This specific kind of Folate, known as Methylfolate, and it is involved in the synthesis of Serotonin as well as other neurotransmitters.  By administering this Folate to individuals suffering from depression, it will create more Serotonin in the brain and ultimately aid in alleviating symptoms.
Biomarkers of treatment response may enable clinicians to target the appropriate drug for each patient. Biomarkers need to have accuracy in real life, sensitivity, specificity, and relevance to depression. Introduction of Depressive Disorder biomarkers into the health care system can increase the overall cost of clinical diagnosis of patients. Because of that, decisions to allocate health research funding must be based on drug effectiveness and cost-effectiveness. The assessment of Depressive Disorder biomarkers should include reliable evidence of associated drug effectiveness, adverse events and consequences. To have the discussions about the Biomarkers in the health and depression disorder of Clinical Research and Biomarkers (WCCRB-2018) this is during September 17-18, 2018 at Toronto, Canada
Link : http://scientificfederation.com/clinical-research-2018/
Continue Reading
Subscribe to: Posts (Atom)